Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05700669 · ClinicalTrials.gov registry record · Phase 1
Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors
A Phase 1 study, sponsored by Valerio Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT05700669 is a Phase 1 study that has completed, run by Valerio Therapeutics. The registered enrollment target is 3 participants.
The verdict
NCT05700669, a Phase 1 study, has completed, sponsored by Valerio Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a phase 1b/2 open-label, multicenter, basket study to determine the safety, anti-tumor activity, tolerability, and pharmacokinetics /pharmacodynamics of AsiDNA in combination with olaparib in participants with recurrent epithelial ovarian cancer, breast cancer and metastatic castration-resistant prostate cancer who have progressed on previous Poly (ADP-ribose) polymerase (PARP) inhibitor therapy. The study will be conducted in two phases. The Phase 1b dose escalation study designed to establish the safety, tolerability, pharmacologically active doses/ maximum tolerated dose and/or recommended phase 2 dose of AsiDNA in combination with olaparib.
Interventions
- DRUG Olaparib
- DRUG AsiDNA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2023-02-20 |
| Est. Completion | 2023-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05700669
The ClinicalTrials.gov registry entry for NCT05700669 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Valerio Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olaparib is the first listed.
NCT05700669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05700669 about?
NCT05700669 is a clinical study titled "Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors". This is a phase 1b/2 open-label, multicenter, basket study to determine the safety, anti-tumor activity, tolerability, and pharmacokinetics /pharmacodynamics of AsiDNA in combination with olaparib in participants with recurrent epithelial ovarian cancer, breast cancer and metastatic castration-resis...
What is the current status of trial NCT05700669?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2023-02-20. Estimated completion is 2023-10-31.
What interventions are being tested in trial NCT05700669?
The interventions under investigation include: Olaparib (DRUG), AsiDNA (DRUG).
Who is sponsoring clinical trial NCT05700669?
This trial is sponsored by Valerio Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.